Perfil
Sara Blum Sherman is currently working as Vice President-Investor Relations at Exscientia AI Ltd.
and Exscientia Plc.
She previously worked as Senior Director-Investor Relations & Strategy at DBV Technologies SA from 2016 to 2020 and as Head-Investor Relations at UroGen Pharma Ltd.
Cargos activos de Sara Blum Sherman
| Empresas | Cargo | Inicio |
|---|---|---|
| EXSCIENTIA PLC | Investor Relations Contact | 01/08/2021 |
Exscientia AI Ltd.
 Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Investor Relations Contact | - |
Antiguos cargos conocidos de Sara Blum Sherman.
| Empresas | Cargo | Fin |
|---|---|---|
| UROGEN PHARMA LTD. | Investor Relations Contact | 01/08/2021 |
| DBV TECHNOLOGIES | Public Communications Contact | 01/09/2020 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| DBV TECHNOLOGIES | Health Technology |
| UROGEN PHARMA LTD. | Health Technology |
| EXSCIENTIA PLC | Health Technology |
| Empresas privadas | 1 |
|---|---|
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Sara Blum Sherman
